Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 201...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2020-04-01
|
| Saila: | Frontiers in Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/article/10.3389/fonc.2020.00515/full |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|